Search

Guardant Health Inc

Lezárt

SzektorEgészségügy

170.69 1.8

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

168.5

Maximum

170.69

Fő mutatók

By Trading Economics

Bevétel

-8.1M

-120M

Értékesítés

33M

335M

Egy részvényre jutó nyereség

-0.89

Profit margin

-35.866

Munkavállalók

2,490

EBITDA

-8.1M

-109M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+12.23% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. okt. 28.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

2.4B

22B

Előző nyitás

168.89

Előző zárás

170.69

Hangulat hírek alapján

By Acuity

50%

50%

150 / 340 Rangsor szerint Healthcare

Guardant Health Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 21. 19:16 UTC

Guardant Health Inc shares are higher today, despite pulling back from an intraday high. The stock remains well above its 20-day moving average.

2026. aug. 20. 23:46 UTC

Guardant Health Inc. shares advanced in after-market trading, remaining above their 20-day moving average amid broader market pressures from rising crude oil prices.

2026. aug. 19. 20:02 UTC

Guardant Health Inc shares are higher today, supported by high trading volume. The stock remains above its 20-day moving average and near recent highs.

2026. aug. 14. 19:36 UTC

Guardant Health Inc shares are lower amid broader market sentiment following disappointing retail sales data, which may impact consumer demand and Federal Reserve interest rate policy.

2026. aug. 13. 23:36 UTC

Guardant Health shares are higher in after-market trading, though no specific news was identified. Broader market sentiment may be influenced by unchanged producer prices.

2026. aug. 12. 19:51 UTC

News

Guardant Health shares are lower as insider sales raise investor concerns. Director Ian Clark sold 14,180 shares for $2.3 million earlier this month.

2026. aug. 10. 19:36 UTC

Guardant Health Inc. shares are higher today, remaining above their 20-day moving average amid rising oil prices driven by geopolitical tensions.

2026. aug. 7. 20:03 UTC

Guardant Health Inc shares are advancing amid strong momentum and high trading volume. Broader market gains coincide with a decline in Treasury yields.

2026. aug. 6. 19:36 UTC

Guardant Health Inc shares are lower today, continuing a decline since Wednesday's close. No specific news was identified to explain the movement.

2026. aug. 3. 19:56 UTC

News

Guardant Health shares are higher as Stifel and Canaccord maintain Buy ratings, raising price targets to $180 and $205, respectively.

2026. júl. 31. 19:51 UTC

News
Social Media

Guardant Health Inc shares are trading higher as analysts raise price targets following strong second-quarter results and an upward revision of full-year revenue guidance.

2026. júl. 30. 23:21 UTC

News
Social Media

Guardant Health reported second-quarter revenue of $335 million, raising 2026 guidance to $1.34 billion to $1.36 billion, boosting shares in after-market hours.

2026. júl. 29. 18:54 UTC

Macro Event
News

Guardant Health Inc shares are higher as investors anticipate Q2 earnings on Thursday, following last quarter's revenue of $301.7 million, up 48.3% year-over-year.

2026. júl. 28. 19:16 UTC

News

Guardant Health shares are lower despite a tribute video featuring Patrick Dempsey and RBC's note on potential coverage tailwinds for the company.

2026. júl. 27. 19:36 UTC

News

Guardant Health Inc shares are lower, continuing a five-day decline despite a 48% year-over-year revenue increase and strong performance in the Shield segment.

2026. júl. 24. 18:36 UTC

Guardant Health Inc shares are lower today, continuing a decline since Thursday's close and remaining below the 20-day moving average.

2026. júl. 20. 20:02 UTC

News

Guardant Health Inc shares are lower today, continuing a decline since Friday amid mixed U.S. market performance and ongoing geopolitical tensions impacting investor sentiment.

Társak összehasonlítása

Árváltozás

Guardant Health Inc Előrejelzés

Célár

By TipRanks

12.23% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 191.56 USD  12.23%

Magas 215 USD

Alacsony 125 USD

21 Wall Street elemző 12 hónapos célárain alapulva a(z)Guardant Health Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

21 ratings

21

Vétel

0

Tartás

0

Eladás

Hangulat

By Acuity

150 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat